Pharma Phorum

JANUARY 25, 2023

Digital therapeutics company Woebot Health has announced enrolment of the first patient in a pivotal clinical trial to evaluate the safety and efficacy of WB001, an investigational therapeutic for postpartum depression (PPD), granted Breakthrough Device designation by the US Food and Drug Administration (FDA) in 2021.

Dosage 105

Dosage FDA 105

Fierce Healthcare

JANUARY 25, 2023

Wave of leading medical schools pull out of U.S. News' annual rankings dmuoio Wed, 01/25/2023 - 17:13

Medical Schools 135

Medical Schools 135

Pharma Phorum

JANUARY 25, 2023

Life sciences marketing has rapidly evolved to mirror that of consumer retail.

Communication 98

Communication 98

Fierce Healthcare

JANUARY 25, 2023

COVID-19 caused surge in heart disease deaths in first year of pandemic: report fdiamond Wed, 01/25/2023 - 08:44

134

134

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.

Dosage

Pharma Phorum

JANUARY 25, 2023

Chemotherapy 98

Chemotherapy Hospitals 98

European Pharmaceutical Review

JANUARY 25, 2023

The first major study on the efficacy of DMT in treating any mental health condition showed a remission rate of 57 percent following a single dose, in a Phase IIa trial for major depressive disorder (MDD).

Labelling 133

Labelling 133

Fierce Pharma

JANUARY 25, 2023

Moderna now in the crosshairs of Sens. Warren, Welch over price tag for COVID vaccine kdunleavy Wed, 01/25/2023 - 13:16

Vaccines 123

Vaccines 123

Fierce Healthcare

JANUARY 25, 2023

Payer startup Angle Health scores $58M to scale operations, expand to new markets agliadkovskaya Wed, 01/25/2023 - 09:42

125

125

Fierce Pharma

JANUARY 25, 2023

Merck's Keytruda dealt another blow in prostate cancer but readies new challenge to AZ's Imfinzi aliu Wed, 01/25/2023 - 10:17

122

122

Fierce Healthcare

JANUARY 25, 2023

State-by-state licensure is anachronistic in the age of teletherapy, providers say aburky Wed, 01/25/2023 - 14:52

116

116

European Pharmaceutical Review

JANUARY 25, 2023

The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for exagamglogene autotemcel (exa-cel), the first regulatory submission for a CRISPR-based medicine.

Labelling 99

Labelling FDA 99

Fierce Healthcare

JANUARY 25, 2023

Health system hospitals, physicians deliver 'marginally' better care at higher cost than independent peers: study dmuoio Wed, 01/25/2023 - 13:52

Hospitals 105

Hospitals 105

Pharmaceutical Technology

JANUARY 25, 2023

A researchers’ team from the University of Texas at San Antonio’s (UTSA) Department of Chemistry and its partners are developing compounds to treat Glioblastoma multiforme (GBM) tumours. UTSA’s partners include UT Health San Antonio’s Department of Obstetrics and Gynecology and Mays Cancer Center.

Compounding 98

Compounding 98

Fierce Pharma

JANUARY 25, 2023

After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE fkansteiner Wed, 01/25/2023 - 18:51

96

96

Pharmafile

JANUARY 25, 2023

Clinical stage biopharmaceutical company Poxel, who focus on developing innovative treatments for chronic, serious diseases with metabolic pathophysiology, has been awarded Orphan Drug Designation (ODD) for two drugs for the treatment of adrenoleukodystrophy (ALD).

FDA 64

FDA 64

European Pharmaceutical Review

JANUARY 25, 2023

Regulators, medicine manufacturers and suppliers have been urged by the World Health Organization (WHO) to take action against contaminated medicines in the supply chain.

88

88

Pharma Phorum

JANUARY 25, 2023

The 501(c)3 non-profit Tidepool, which seeks to empower the next generation of innovations in diabetes management, has announced that the US Food and Drug Administration (FDA) has cleared Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D) in those six years old and above.

FDA 59

FDA 59

Fierce Pharma

JANUARY 25, 2023

As Scangos bids adieu, Vir taps Bayer dealmaker De Backer as its next CEO fkansteiner Wed, 01/25/2023 - 11:09

83

83

Fierce Healthcare

JANUARY 25, 2023

Medicare officials call for gradual shift in calculation of Medicare Advantage benchmarks to reflect growing popularity rking Wed, 01/25/2023 - 17:10

76

76

Pharmaceutical Commerce

JANUARY 25, 2023

Expansion expected to help tackle health issues at a faster rate, company says us

52

52

Pharma Phorum

JANUARY 25, 2023

An FDA advisory committee has recommended approval of Cidara Therapeutics’ once-weekly antifungal therapy rezafungin, setting it up to become the first new option for severe infections caused by Candida species in a decade.

Documentation 52

Documentation FDA 52

Pharmaceutical Commerce

JANUARY 25, 2023

Annual report finds continuing impact of COVID-19 on global markets us

52

52

PharmaVoice

JANUARY 25, 2023

As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands

52

52

Pharma Phorum

JANUARY 25, 2023

Buoyed by encouraging mid-stage clinical results for its idiopathic pulmonary fibrosis therapy bexotegrast, Pliant Therapeutics filed a $175million public offering, and then swiftly raised its target to $250million on strong early interest.

52

52

PharmaVoice

JANUARY 25, 2023

The pharma giant's CEO Joaquin Duato and CFO Joseph Wolk showed that they're optimistic about reaching lofty goals despite hard economic times

52

52

Pharma Phorum

JANUARY 25, 2023

AstraZeneca followed a long and arduous road to bring its CTLA4 inhibitor Imjudo to market, and will now have to defend its new product from a patent infringement complaint brought by Bristol-Myers Squibb in the US.

Chemotherapy 52

Chemotherapy FDA 52

Pharmafile

JANUARY 25, 2023

US-based Thermo Fisher Scientific has announced the launch of its CE-IVD marked Applied Biosystems Taqpath Seq HIV-1 Genotyping kit.

Communication 52

Communication 52

Fierce Healthcare

JANUARY 25, 2023

A record 16.3M people signed up for coverage on ACA exchanges during open enrollment, CMS says pminemyer Wed, 01/25/2023 - 16:40

72

72

Pharmafile

JANUARY 25, 2023

US-based pharmaceutical company, Eli Lilly and Company, has announced plans to invest $450m in its manufacturing facilities at Research Triangle Park in North Carolina, US.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JANUARY 25, 2023

After a tumultuous year that weathered the continued impact of a bear market , many in biotech are looking for signs of improvement in 2023. However, industry experts have buckled up in anticipation of continued challenges this year.

Communication 69

Communication 69

Pharmacy Times

JANUARY 25, 2023

Research showed that 600 hospital beds filled with patients with severe illness would be enough to reimplement (mask mandates to stop the spread of infection.

Hospitals 65

Hospitals 65

Pharmaceutical Technology

JANUARY 25, 2023

Clinical trials require precision and faultless execution for hypotheses to become therapies. For most of pharmaceutical history, this has made the potential benefits from outsourcing elements of these trials elusive.

Vaccines 59

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 59

Pharmacy Times

JANUARY 25, 2023

Luke Gormley, PharmD, BCPS, discusses how pharmacists are involved in the management of inclisiran.

65

65

Pharmaceutical Technology

JANUARY 25, 2023

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022.

Vaccines 59

Vaccines 59

Pharmafile

JANUARY 25, 2023

FDA 40

FDA 40

Pharmaceutical Technology

JANUARY 25, 2023

The Saudi Food & Drug Authority (SFDA) has approved the manufacturing and distribution of Alvotech and Bioventure’s AVT02 (adalimumab). The monoclonal antibody AVT02 is the approved biosimilar for AbbVie ’s Humira (adalimumab).

59

59